Regarding the future possibilities of PP2A modulators as cancer therapeutics, it has been highly suggested that achieving substrate specificity by directly targeting specific PP2A regulatory complexes would uphold better tolerability and cancer inhibition. This evidence concerns the gene PTPA and cancer.